Elicera Therapeutics AB (OSTO:ELIC) Total Equity: kr18.30 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ELIC Elicera Therapeutics AB OSTO:ELIC
25 GF Score
Price kr2.62
! 1 Warning Sign
View Full Analysis

What is Elicera Therapeutics AB Total Equity?

Elicera Therapeutics AB OSTO:ELIC -1.50% 25 Total Equity is kr18.30 Mil as of Mar. 2026. GuruFocus rates OSTO:ELIC with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Elicera Therapeutics AB's total equity for the quarter that ended in Mar. 2026 was kr18.30 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Elicera Therapeutics AB Total Equity Historical Data

* Premium members only.

The historical data trend for Elicera Therapeutics AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicera Therapeutics AB Total Equity Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 52.24 32.80 16.40 20.77 23.36

Elicera Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.76 30.02 30.33 23.36 18.30
OSTO:ELIC
25GF Score
Elicera Therapeutics AB OSTO:ELIC
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicera Therapeutics AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Elicera Therapeutics AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=27.421-4.06
=23.36

Elicera Therapeutics AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=20.9-2.599
=18.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr18.30 Mil mean?
Elicera Therapeutics AB (OSTO:ELIC) has a Total Equity of kr18.30 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Elicera Therapeutics AB and its competitors.
Is Elicera Therapeutics AB's Total Equity too high?
Elicera Therapeutics AB's current Total Equity is kr18.30 Mil. Overall, Elicera Therapeutics AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's Total Equity compare to VRTX and REGN?
Elicera Therapeutics AB's Total Equity of kr18.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Elicera Therapeutics AB and its competitors. Elicera Therapeutics AB's current Total Equity is kr18.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (OSTO:ELIC) has a current Total Equity of kr18.30 Mil. The current Total Equity is kr18.30 Mil. Elicera Therapeutics AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Elicera Therapeutics AB (OSTO:ELIC), the current Total Equity is kr18.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicera Therapeutics AB Business Description

Other Exchanges 8E8:Germany
Address Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, 412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
25GF Score

Get the complete analysis for OSTO:ELIC

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.62
Price